TI
BMRN icon

Turner Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Turner Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,270
Closed -$519K – 224
2016
Q4 		$519K Hold
6,270
– – 0.21% 144
2016
Q3 		$580K Buy
+6,270
New +$590K 0.19% 139
2014
Q1 		– Sell
-57,484
Closed -$4.04M – 645
2013
Q4 		$4.04M Sell
57,484
-163,805
-74% -$11.1M 0.07% 282
2013
Q3 		$16M Sell
221,289
-200,650
-48% -$13.3M 0.26% 130
2013
Q2 		$23.5M Buy
+421,939
New +$26.3M 0.32% 111

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Turner Investments's BMRN Position: Q1 2017 in Review

Turner Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 6,270 shares — an estimated $519K sold.

Turner Investments first reported a position in BMRN in Q2 2013 and held it in 5 quarters. The position peaked at $23.5M in Q2 2013. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

  • Turner Investments reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Turner Investments sold 6,270 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $519K.
  • Turner Investments first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Turner Investments's BioMarin Pharmaceuticals position peaked at $23.5M in Q2 2013.
  • 418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.